Steve. you, Thank
to our inflammatory treat on is a melanocortin develop to diseases know, and you highly drugs safe As for effective as pipeline autoimmune focus and with establishing safety. a the system of medicines unparallel and effective target
to coming programs active highly development have clinical multiple activities. research productive advance from agonist on melanocortin our X We pending all programs resources, clinical ready into with based new of these
disease. previously you the III for Phase we enrollment completed study As MELODY dry reported, in have PL-XXXX patient X eye
We've in key reminder, inflammation that signs across symptoms eye that and cause enrolled a a resolving the show separation a agonist works patients conducted eye dry interim for initial the PL-XXXX MELODY-X, surface on efficacy cause disease. for is which clinical by topically multiple dry of XXX statistical analysis also of of disease. is an As ocular melanocortin delivered
Importantly, PLXXXX has safety excellent ocular tolerability. and
have year-end. we by complete are data to about the treatment, patient last working to the With line top randomized
potential for dry be emerging and the disease. eye of PL-XXXX tolerability profile a given believe to leading the efficacy treatment We
on. Moving
interim [indiscernible] PLXXXX quarter inflammation than inflammation. it blocking improve disease is model possibility and the coupled in treating that Our Supporting provides to data safety and study inflammatory in of bowel with clauses disease. a our of selective the evaluating also and and to the this pathological PLXXXX supply a and disease state oral to treatment development, rather XXXX. first with demonstrating Phase assessment Dissolving melanocortin- efficacy on colitis receptor an healthy II oral resolve agonist track studies of for oral patient preclinical clinical PLXXXX
our study, with diabetic open-label line data Finally, is the part patients which XXXX top as study Phase disease in in for of kidney on first breakout a track is well. II
I'd the like that anticipating calendar X to XXXX. in studies take quarter minute to new highlight starting of clinical a we are first
agonist men II Vyleesi phosphodiesterase-X efforts inhibitor and study market. a dysfunction. have with is such formulation a Viagra. treatment I'm combining of a as to inadequate with fail The and PDX evaluating bremelanotide, extension these Cialis inhibitor, melanocortin an sexual commercial dysfunction and represent response a are first as is or large This drugs our and a such an Phase sorry, erectile XX% Approximately of underserved novel
The for highly are these options as failure only such penile injections invasive treatment or implants. patients penile
patients the to the as synergistic agonists. GLP-X The that trials PD-X agonist study Wegovy. of news things Ozempic obese the X GLP-X with hear receptor are inhibitor a on erectile We have dysfunction. clinical being bremelanotide the or previously time. as combining all treatment for such used same them clinical agonist effects conducted a These in a And taking for are drugs showing will evaluate melanocortin
the obese are that patients. current for standard drugs the are of These care treating
not action importantly, overall a drugs loss be and of maintenance. targeting loss for important growing with established This treatment will the to will we but goal treatment weight of require affect is the different that management. variety strongly melanocortin obesity We believe driving and overall rapidly, mechanisms obesity switch treatment now will only management. drugs As part weight weight believe loss weight of of weight system drug from that an future
experience melanorcortin-based extensive in well therapeutics. development development of be obesity, agonist clinical including for to leader in a melanocortin we X are of our design With treating and the the studies, positioned
quarters few increased all XX% net before excited quarterly prior Listen, questions. that Notably, by metrics. are quarterly the as again, revenue with quarter. another to Listen, we to operating we continues to also Vyleesi, expenses. are pleased quarter. over a Vyleesi want revenue X highlights Just product leasing previous operating double-digit we across growth product very net just so XX% I value the just on reiterate move consecutive Prescriptions dispensed over exceed
X quarter in studies as II of As 'XX readout are, new The patients bremelanotide that with we in just PDX co-formulation data with the we dysfunction studies erectile failed corn a evaluate clinical in we're well. programs first 'XX X starting planning to have calendar as initiating therapy. the said, stated, first-line inhibitor we'll the of with Phase one, with
move or So for in on to them, they other isn't therapy. to need aggressive more words, Viagra and Cialis working
The second, a taking GLP-X bremelanotide of evaluate we'll the to agonist obese melanocortin-X agonist. patients the addition
ocular impressive continue advances. Our to programs make
profile the very for at year. eye treatments. MELODY-X Phase study is excited fully the emerging highly about III product end our study, from enrolled the differentiated dry remain We of current DED PL-XXXX, data coming Our
to we excited finally, We've really multiple melanocortin and but treatment have novel excellent it's broad efficacy well. for going we're this a talked as disease become got think a think the dry leading We've eye it can And about and tolerability, And past, PL-XXXX. across in signs for I we're symptoms. agonist glaucoma.
II to track you move Palatin an to fiscal year for IND to sometime call. and listening first quarter I'd clinical the on the the around now then -- the XXXX XXXX Phase end the file are We on of in thank half first in of studies. to like
website, clinical You our science can programs www.palatin.com. find and additional information on our on
Steve additional for and on to now you the would up at information find You call the support, And I can open certainly like interest, Vyleesi your thank vyleesi.com. Vyleesi your website, and we'll to also questions.
